Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Published:2022-08-23 Issue:3 Volume:12 Page:2731-2738
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Chon Young Eun¹,Cheon Jaekyung²,Kim Hyeyeong³,Kang Beodeul²,Ha Yeonjung¹,Kim Do young⁴,Hwang Seong Gyu³,Chon Hong Jae²^ORCID,Kim Beom Kyung⁴^ORCID

Affiliation:

1. Department of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam Republic of Korea

2. Department of Medical oncology CHA Bundang Medical Center, CHA University Seongnam Republic of Korea

3. Department of Internal Medicine Ulsan University Hospital, University of Ulsan College of Medicine Ulsan Republic of Korea

4. Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5161

Reference26 articles.

1. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

2. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

3. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

4. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02

2. Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma;Frontiers in Oncology;2024-06-27

3. Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis;Liver Cancer;2024-05-22

4. A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma;Clinical Cancer Research;2024-04-19

5. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma;Cancers;2024-03-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3